JP7358367B2 - 抗グリコｍｕｃ１抗体およびその使用 - Google Patents

抗グリコｍｕｃ１抗体およびその使用 Download PDF

Info

Publication number
JP7358367B2
JP7358367B2 JP2020543460A JP2020543460A JP7358367B2 JP 7358367 B2 JP7358367 B2 JP 7358367B2 JP 2020543460 A JP2020543460 A JP 2020543460A JP 2020543460 A JP2020543460 A JP 2020543460A JP 7358367 B2 JP7358367 B2 JP 7358367B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020543460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510307A (ja
Inventor
ホワイト，セイヤー
Original Assignee
ジーオー セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーオー セラピューティクス，インコーポレイテッド filed Critical ジーオー セラピューティクス，インコーポレイテッド
Publication of JP2021510307A publication Critical patent/JP2021510307A/ja
Priority to JP2023165289A priority Critical patent/JP2024001073A/ja
Application granted granted Critical
Publication of JP7358367B2 publication Critical patent/JP7358367B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2020543460A 2017-10-24 2017-10-24 抗グリコｍｕｃ１抗体およびその使用 Active JP7358367B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023165289A JP2024001073A (ja) 2017-10-24 2023-09-27 抗グリコｍｕｃ１抗体およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023165289A Division JP2024001073A (ja) 2017-10-24 2023-09-27 抗グリコｍｕｃ１抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2021510307A JP2021510307A (ja) 2021-04-22
JP7358367B2 true JP7358367B2 (ja) 2023-10-10

Family

ID=66247577

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543460A Active JP7358367B2 (ja) 2017-10-24 2017-10-24 抗グリコｍｕｃ１抗体およびその使用
JP2023165289A Pending JP2024001073A (ja) 2017-10-24 2023-09-27 抗グリコｍｕｃ１抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023165289A Pending JP2024001073A (ja) 2017-10-24 2023-09-27 抗グリコｍｕｃ１抗体およびその使用

Country Status (10)

Country Link
EP (1) EP3700936A4 (enExample)
JP (2) JP7358367B2 (enExample)
KR (2) KR102832078B1 (enExample)
CN (1) CN111479828B (enExample)
AU (1) AU2017436815B2 (enExample)
BR (1) BR112020008001A2 (enExample)
CA (1) CA3078812A1 (enExample)
IL (1) IL274202A (enExample)
MX (1) MX2020004220A (enExample)
WO (1) WO2019083506A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024001073A (ja) * 2017-10-24 2024-01-09 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300104A (en) * 2020-07-31 2023-03-01 Scherer Technologies Llc R P Antibody specific for mucin-1 and methods of using it
CA3230370A1 (en) * 2021-08-27 2023-03-02 Peptron, Inc. Novel anti-muc1 antibody and use thereof
CA3241162A1 (en) * 2021-12-21 2023-06-29 Rinse KLOOSTER Binding domains against cancer-associated muc1
CN115068610B (zh) * 2022-01-27 2024-04-16 中国农业大学 抑制乳腺癌细胞中muc1表达的物质在降低抗乳腺癌药物耐药性中的应用
TW202444432A (zh) * 2023-04-13 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｅｇｆｒ和ｍｕｃ１的抗原結合分子、其藥物偶聯物及其醫藥用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors
US20160145343A1 (en) 2013-07-15 2016-05-26 Cell Signaling Technology, Inc, Anti-mucin 1 binding agents and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
AU2007304590A1 (en) * 2006-10-04 2008-04-10 Cancer Research Technology Limited Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
EP2014302A1 (en) * 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
CN101978054B (zh) * 2007-12-05 2013-05-29 协和发酵麒麟株式会社 能够与肝素结合性表皮生长因子样生长因子结合的单克隆抗体
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2015120180A1 (en) * 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
AU2015254257B2 (en) * 2014-04-28 2021-02-25 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
BR112020008001A2 (pt) * 2017-10-24 2020-10-20 Go Therapeutics, Inc. anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors
US20160145343A1 (en) 2013-07-15 2016-05-26 Cell Signaling Technology, Inc, Anti-mucin 1 binding agents and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024001073A (ja) * 2017-10-24 2024-01-09 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用

Also Published As

Publication number Publication date
WO2019083506A1 (en) 2019-05-02
KR20200067885A (ko) 2020-06-12
EP3700936A1 (en) 2020-09-02
CA3078812A1 (en) 2019-05-02
JP2021510307A (ja) 2021-04-22
KR20230165874A (ko) 2023-12-05
KR102608763B1 (ko) 2023-11-30
JP2024001073A (ja) 2024-01-09
KR102832078B1 (ko) 2025-07-08
CN111479828A (zh) 2020-07-31
AU2017436815A1 (en) 2020-04-23
AU2017436815B2 (en) 2025-05-29
MX2020004220A (es) 2020-10-05
EP3700936A4 (en) 2021-05-26
IL274202A (en) 2020-06-30
BR112020008001A2 (pt) 2020-10-20
CN111479828B (zh) 2024-07-05

Similar Documents

Publication Publication Date Title
US12065504B2 (en) Anti-glyco-MUC1 antibodies and their uses
US20230126689A1 (en) Anti-glyco-cd44 antibodies and their uses
JP7358367B2 (ja) 抗グリコｍｕｃ１抗体およびその使用
US20250304716A1 (en) Anti-glyco-muc1 antibodies and their uses
JP2024536722A (ja) 抗グリコｃｍｅｔ抗体およびその使用
JP2024534910A (ja) 抗グリコｌａｍｐ１抗体およびその使用
JP2024531915A (ja) 抗グリコｍｕｃ抗体およびその使用
JP2024512324A (ja) 抗グリコｃｄ４４抗体およびその使用
HK40114974A (zh) 抗糖-muc4抗体及其用途
CN118354788A (zh) 抗糖-muc4抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230927

R150 Certificate of patent or registration of utility model

Ref document number: 7358367

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150